You are here: Industry Insights > Market News > Parexel launches Health Advances Asia, expanding global footprint with Hong Kong, S.A.R., China base

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Brexpiprazole Intermediate CAS:70500-72-0

Brexpiprazole CAS:913611-97-9

3-BROMOPHENANTHRENE

2-FLUORO-4-(TRIFLUOROMETHYL)BENZOPHENONE

3-BROMO-4-FLUOROBIPHENYL

9-TRIFLUOROACETYLANTHRACENE

Parexel launches Health Advances Asia, expanding global footprint with Hong Kong, S.A.R., China base

fiercepharmaJuly 28, 2019

Tag: PAREXEL , Health Advances Asia , global footprint

Favorites

The so-called Health Advances Asia Limited subsidiary, which forms part of Parexel's consulting unit, is set up to "support development of global expansion strategies for Asia/Pacific and multinational companies from new Hong Kong, S.A.R., China presence," according to the firm.

It will be led by biopharma and medtech veteran Gary Cheng, who will be in charge of the local team. Cheng, who counts Novartis, BD, Chiron, Alere and Aventis among his former employers, will also work with Vivek Mittal, a long-time partner at Health Advances in its San Francisco office who will now be based in Hong Kong, S.A.R., China Special Administrative Region in China.

Previous:Key European committee backs GW's Epidyolex, Bayer's Vitrakvi and more

Next:GOP senators distance themselves from Grassley, Trump's efforts to cut drug prices

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Parexel launches Health Advances Asia, expanding global footprint with Hong Kong, S.A.R., China base | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

Parexel launches Health Advances Asia, expanding global footprint with Hong Kong, S.A.R., China base

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

Parexel launches Health Advances Asia, expanding global footprint with Hong Kong, S.A.R., China base

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>